Response to an Oral Nutritional Supplement for Chronic Renal Failure Patients

David B. Cockram, Linda W. Moore, Sergio R. Acchiardo

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


■ Objective: To compare biochemical responses, nutrient intake, formula acceptability, and gastrointestinal tolerance during oral supplementation of chronic renal failure (CRF) patients using two medical nutritional products. ■ Design: Prospective, randomized, two-group, unblinded, parallel design. ■ Setting: Two university-affiliated hospitals. ■ Patients: Eighteen CRF patients (4 caucasian/14 African-American; 5 female/13 male) at risk for malnutrition but without evidence of abnormal nutrient metabolism. ■ Intervention: Oral supplementation using either clinical product EN-8915 or Polycose Glucose Polymers (Ross Products Division, Abbott Laboratories, Columbus, OH) for 4 weeks at a rate of 10 kcal/kg · d−1. ■ Main outcome measures: Blood chemistries, self-reported nutrient intake and gastrointestinal (GI) tolerance, and sensory evaluation data. ■ Results: Both products increased energy intake by approximately 10 kcal/kg · d−1 without influencing gastrointestinal tolerance during 4 weeks of oral supplementation. Protein, vitamin, and mineral intakes were higher in patients ingesting the clinical product than Polycose. Blood chemistries were unchanged. ■ Conclusion: Short-term oral supplementation with either clinical product EN-8915 (a similar product is now marketed as Suplena Specialized Liquid Nutrition) or Polycose effectively increased energy intake. GI tolerance was excellent for both products.

Original languageEnglish (US)
Pages (from-to)78-85
Number of pages8
JournalJournal of Renal Nutrition
Issue number2
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Nephrology


Dive into the research topics of 'Response to an Oral Nutritional Supplement for Chronic Renal Failure Patients'. Together they form a unique fingerprint.

Cite this